{"id":"tookad-vtp","safety":{"commonSideEffects":[{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Dysuria"},{"rate":null,"effect":"Urinary tract infection"},{"rate":null,"effect":"Perineal pain"},{"rate":null,"effect":"Photosensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1276678","moleculeType":"Small molecule","molecularWeight":"525.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TOOKAD (padeliporfin) is a lipophilic photosensitizer that localizes in the vasculature of tumors. Upon activation by 763 nm laser light, it generates singlet oxygen and reactive oxygen species that cause immediate vascular thrombosis and tumor ischemia, leading to rapid necrosis of the treated tissue. The VTP (vascular-targeted photodynamic therapy) approach selectively targets tumor blood vessels rather than tumor cells directly.","oneSentence":"TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:49.957Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Localized prostate cancer (intermediate and high-risk disease)"}]},"trialDetails":[{"nctId":"NCT04620239","phase":"PHASE3","title":"ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study","status":"RECRUITING","sponsor":"Steba Biotech S.A.","startDate":"2021-03-22","conditions":"Transitional Cell Cancer of Renal Pelvis and Ureter","enrollment":100},{"nctId":"NCT03315754","phase":"PHASE2","title":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Steba Biotech S.A.","startDate":"2017-10-02","conditions":"Localized Prostate Cancer","enrollment":50},{"nctId":"NCT00946881","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2009-07","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03849365","phase":"PHASE4","title":"Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer","status":"TERMINATED","sponsor":"Steba Biotech S.A.","startDate":"2019-01-21","conditions":"Low Risk Prostate Cancer","enrollment":23},{"nctId":"NCT04017325","phase":"","title":"European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2016-03-17","conditions":"Cancer of the Prostate","enrollment":374},{"nctId":"NCT04225299","phase":"PHASE3","title":"Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"Steba Biotech S.A.","startDate":"2020-03-31","conditions":"Localized Prostate Cancer","enrollment":""},{"nctId":"NCT01310894","phase":"PHASE3","title":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2011-02","conditions":"Prostate Cancer","enrollment":413},{"nctId":"NCT01573156","phase":"PHASE1, PHASE2","title":"Vascular Targeted Photodynamic Therapy T1a Renal Tumours","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-05","conditions":"Renal Cancer","enrollment":5},{"nctId":"NCT00707356","phase":"PHASE2","title":"Study of WST11 in Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2008-09","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT01875393","phase":"PHASE3","title":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2013-05","conditions":"Prostate Cancer","enrollment":81},{"nctId":"NCT00975429","phase":"PHASE2","title":"Study Using WST11 in Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":86},{"nctId":"NCT00305929","phase":"PHASE2","title":"Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure","status":"COMPLETED","sponsor":"STEBA France","startDate":"2006-03","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT00312442","phase":"PHASE2, PHASE3","title":"Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy","status":"TERMINATED","sponsor":"STEBA France","startDate":"2006-05","conditions":"Prostate Cancer","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TOOKAD VTP","genericName":"TOOKAD VTP","companyName":"Steba Biotech S.A.","companyId":"steba-biotech-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis. Used for Localized prostate cancer (intermediate and high-risk disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}